Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 50 years of age at the time of enrollment.~* Signed the informed consent document.~* Subject judged to be healthy by a qualified physician~Exclusion Criteria:~* Abnormal physical findings of clinical significance at the screening examination~* Significant abnormal laboratory values at the Screening Visit.~* Clinically significant symptoms or conditions that may have placed the subject at an unacceptable risk as a participant in the trial, or that may have interfered with the absorption, distribution, metabolism or excretion of the IMP.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- STS101 1.5 mg (Type: EXPERIMENTAL): STS101 (dihydroergotamine nasal powder), 1.5 mg
- STS101 3.0 mg (Type: EXPERIMENTAL): STS101 (dihydroergotamine nasal powder), 3.0 mg
- STS101 6.0 mg (Type: EXPERIMENTAL): STS101 (dihydroergotamine nasal powder), 6.0 mg
- DHE intramuscular injection (Type: ACTIVE_COMPARATOR): Dihydroergotamine mesylate
- DHE nasal spray (Type: ACTIVE_COMPARATOR): Dihydroergotamine mesylate

Based on this trial design, predict the completion outcome and termination type (if applicable).